This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignees: Amcure Gmbh, Ruprecht-Karls-Universität. Active years: 2020.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 4 
1 out of 7 Years Active: 2020
Title: Thomas Lindner: Innovator in Cancer Treatment
Introduction
Thomas Lindner is a notable inventor based in Eppelheim, Germany. He has made significant contributions to the field of cancer treatment through his innovative research and development of therapeutic compounds.
Latest Patents
Lindner holds a patent for "CD44v6-derived cyclic peptides for treating cancers and angiogenesis related diseases." This invention relates to compounds, pharmaceutical compositions, and methods for treating various forms of cancer and diseases associated with angiogenesis using cyclic peptides. He has 1 patent to his name.
Career Highlights
Throughout his career, Thomas Lindner has worked with prominent organizations, including Amcure GmbH and Ruprecht-Karls-Universität. His work has focused on developing effective treatments for cancer, showcasing his dedication to improving patient outcomes.
Collaborations
Lindner has collaborated with esteemed colleagues such as Alexandra Matzke-Ogi and Véronique Orian-Rousseau. These partnerships have furthered his research and contributed to advancements in cancer therapies.
Conclusion
Thomas Lindner's innovative work in developing cyclic peptides for cancer treatment highlights his commitment to addressing critical health challenges. His contributions to the field are invaluable and continue to inspire future research in oncology.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile